In this article, we will list the 15 worst 52-week low stocks to buy now according to short sellers.

The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation. After weeks and months of uncertainty about what the Fed would do, certainty is slowly creeping into the market, helping bolster investor sentiments.

With the S&P 500 back to record highs, it’s the Nasdaq 100 that appears to be making the most significant moves, having gained more than 3% in the aftermath of the 50 basis point interest rate cut. The spike in the tech-heavy U.S. index is a clear indicator that tech stocks are well poised to edge higher after weeks of stagnation.

The interest rate cut is expected to positively impact short-term bank borrowing costs, making it easy for people and businesses to access cheap capital to fuel economic activity that has been slowing in recent months. Additionally, it should positively impact various consumer products like mortgages, auto loans, and credit cards.

While there were concerns that the U.S. economy was slowing due to disappointing employment data and a slowdown in the manufacturing sector, Fed Chair Jerome Powell reiterated that the 50 basis point cut was all about ‘recalibrating’ the economy.

Initially, there were concerns that the FED coming through with a 50 basis point would fuel fears about the health of the U.S. economy and consequently rattle stocks. However, that was not the case as stocks rallied, signaling that investors were optimistic about the economy and long-term outlook in the market.

Tom Porcelli, top U.S. economist at PGIM Fixed Income Policy, thinks the Fed policy was set up to handle much more inflation. Now that inflation is getting close to the target, the Fed can start to ease off on the tight money they’ve been applying. Consequently, the aggressive interest rate cut is not because we’re heading into a recession but because we want to keep the economic growth going.

While the focus will be on stocks that have been edging higher for the year, the focus is slowly shifting to stocks that have bottomed and that market participants are bearish on. Stocks that have been battered to 52-week lows are increasingly turning out to be bargains, especially on the monetary policy improving after months of uncertainty. Nevertheless, it is unclear whether stocks with high short interest rates will bounce back after coming under immense pressure over the past nine months.

With the Fed cutting interest rates with a bang, CNBC commentator and Fast Money host Jim Cramer believes investors should start paying attention to stocks well poised to benefit from a low interest rate environment. Some stocks to consider are companies providing products and services that depend on consumers’ purchasing power.

With that, let’s take a look at the worst 52-week low stocks to buy now, according to short sellers.

Our Methodology

We used the Finviz screener to find stocks that were trading near their 52-week lows and that had high short interest (at least 5%). We then picked the stocks with the highest short interest and ranked them in ascending order of this metric. We have also added the hedge fund sentiment for these stocks.

At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers

15. Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

52 Week Range: $1.77 – $11.41

Current Share Price: $1.94

Short % of Shares Outstanding: 6.99%

Number of Hedge Funds holding stakes as of Q2 2024: 5

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) is a clinical-stage dermatology therapeutics company that develops medications for the treatment of skin diseases. Its product pipeline comprises YCANTH (VP-102) for treating common warts and has completed a phase II clinical trial to treat external genital warts.

It remains one of the worst 52-week low stocks to buy now, according to short sellers, owing to growing concerns about the company’s ability to turn a profit. In its recent quarter, it posted a loss of $67 million, taking its trailing 12-month loss to $87 million.

The soaring net loss has been the catalyst behind Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) ‘s soaring short interest, which stands at 6.99%. Likewise, the gross profit margin has been negative, at -60.48%, suggesting profit challenges.

Nevertheless, the company is showing signs of underlying growth in product revenue for its flagship product, YACNTH, improving to $4.9 million. Total revenues in the second quarter totaled $5.2 million. Nevertheless, analysts at RBC Capital reduced their price target on the stock to $13 from $14, citing weakness on the launch of the company’s flagship YCANTH for molluscum contagiosum.

In the second quarter of 2024, 5 hedge funds in the database of Insider Monkey held stakes worth $84.51 million in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), up from 2 in the preceding quarter worth $65.71 million.

14. Five9, Inc. (NASDAQ:FIVN)

52 Week Range: $26.60 – $92.40

Current Share Price: $27.77

Short % of Shares Outstanding: 7.64%

Number of Hedge Fund Investors in Q2 2024: 34

Five9, Inc. (NASDAQ:FIVN) is a technology company that provides intelligent cloud software for contact centers. It offers a cloud platform that delivers a suite of applications that enables the breadth of contact center-related customer service, sales, and marketing functions.

Five9, Inc. (NASDAQ:FIVN)’s core business has been under pressure in recent years as the growth in e-commerce translates to fewer in-person visits in stores, therefore affecting demand for contact-center software solutions. Fears about competition, doubts regarding the lasting effects of artificial intelligence on the company, and the overall decline in economic conditions have all darkened the stock’s outlook.

The consumer division, which is among the company’s biggest, has been particularly hard-hit lately as fewer clients are hiring call center agents, putting pressure on Five9’s model that relies on seat-based revenue. Consequently, Five9, Inc. (NASDAQ:FIVN)’s revenue growth slowed to 13% compared to the previous year, a drop from 28% and 17% in 2022 and 2023, respectively.

Additionally, the company’s management has forecasted a 16% revenue growth for 2024, which some view as overly optimistic given the poor start to the year. These declining sales figures have also negatively affected the company’s quarterly stock performance.

The deteriorating macroeconomics has taken a significant toll on the stock’s sentiments in the market, resulting in it dropping near its 52-week lows. Nevertheless, the company’s growth metrics have started showing signs of improvement. For instance, revenue grew by 13% in the second quarter to $252.1 million, with net loss shrinking to $12.8 million from $21.7 million a year ago.

At the end of Q2 2024, 34 hedge funds were eager on Five9, Inc. (NASDAQ:FIVN), compared to 38 in the previous quarter. Of those, Alyeska Investment Group was the largest shareholder in the company and disclosed a position worth $94.22 million.

In its Q2 2023 investor letter, Brown Capital Management Mid Company Fund provided the following insight regarding Five9, Inc. (NASDAQ:FIVN):

“Five9, Inc. (NASDAQ:FIVN) is a leader in cloud-based contact-center software, which serves as the routing engine to connect callers to agents. With the growth of e-commerce, consumers are making fewer in-person visits to stores but contacting companies more frequently, driving the need for world-class contact-center software solutions like Five9’s. It has been a tough couple of years for Five9’s stock and this quarter provided no relief. Competitive concerns, questions about AI’s long-term impact on the business and deteriorating macroeconomic conditions have all cast clouds over the company’s stock. Five9’s consumer segment, one of its largest divisions, has really struggled of late as clients hire fewer call-center agents, pressuring Five9’s seat-based revenue model. Total revenue growth decelerated to 13% year-over-year in the most recent quarter, down from 28% and 17% in 2022 and 2023, respectively. Moreover, management guided to 16% for the full year 2024, which some consider optimistic given the weak start to the year. These worsening sales trends further weighed on shares during the quarter.

Looking through the current industry doldrums, we see a bright future for Five9. The company inked its largest deal ever during the quarter, which will generate more than $50 million in annual revenue once fully rolled out. We believe this is an important signal of Five9’s long-term potential. The company is attacking a $60 billion market opportunity, is winning new business at industry-leading rates and is gaining share from legacy incumbents stuck with antiquated technology. We continue to assess the potential threat of AI, but so far it has provided an uplift to company results. The company’s AI product is very popular with large enterprises as it assists agents with customer interactions and can sometimes be used to fully automate interactions. Far from shrinking the number of industry seats, as some fear, management said revenue per seat doubles when customers adopt their AI applications. We expect sales growth to pick up markedly in the coming years, which should result in much stronger stock performance.”